Short Interest in Bio-Path Holdings, Inc. (NASDAQ:BPTH) Rises By 179.6%

Bio-Path Holdings, Inc. (NASDAQ:BPTH) was the target of a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 86,400 shares, an increase of 179.6% from the November 30th total of 30,900 shares. Currently, 2.0% of the company’s shares are sold short. Based on an average daily volume of 3,000,000 shares, the days-to-cover ratio is presently 0.0 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Bio-Path stock. Armistice Capital LLC bought a new stake in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned 4.66% of Bio-Path at the end of the most recent reporting period. Hedge funds and other institutional investors own 5.74% of the company’s stock.

Bio-Path Stock Performance

Shares of NASDAQ:BPTH traded down $0.21 during mid-day trading on Friday, reaching $1.14. 491,588 shares of the company were exchanged, compared to its average volume of 1,509,598. Bio-Path has a 1 year low of $0.59 and a 1 year high of $12.00. The firm’s 50-day simple moving average is $0.89 and its 200 day simple moving average is $1.24.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on shares of Bio-Path in a report on Thursday. They issued a “sell” rating on the stock.

Bio-Path Company Profile

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.